Study Design of HOMED-BP: Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure

The issue of how far blood pressure (BP) should be lowered to achieve the greatest reduction in the risk of cardiovascular disease has been a matter of scientific debate. Although a few trials tried to answer this question, they failed to convincingly show the optimal target BP level, in part becaus...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental hypertension (1993) 2003-04, Vol.25 (3), p.143-144
Main Authors: Fujiwara, Tohru, Matsubara, Mitsunobu, Ohkubo, Takayoshi, Imai, Yutaka
Format: Article
Language:English
Subjects:
Adult
Aged
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - therapeutic use
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood Pressure Monitoring, Ambulatory - methods
Calcium Channel Blockers - therapeutic use
Cardiology. Vascular system
Cardiovascular Diseases - complications
Cardiovascular Diseases - mortality
Clinical manifestations. Epidemiology. Investigative techniques. Etiology
Humans
Hypertension - complications
Hypertension - diagnosis
Hypertension - drug therapy
Japan
Medical sciences
Middle Aged
Prospective Studies
Randomized Controlled Trials as Topic
Self Care - methods
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The issue of how far blood pressure (BP) should be lowered to achieve the greatest reduction in the risk of cardiovascular disease has been a matter of scientific debate. Although a few trials tried to answer this question, they failed to convincingly show the optimal target BP level, in part because of poor reproducibility and wide variability of conventional casual BP measurement used in these trials. On the other hand, in Japan, calcium antagonist (Ca-A) and angiotensin converting enzyme inhibitor (ACE-I) have been two major medications of initial therapy for hypertension, while angiotensin II receptor antagonist (ARB), which has recently been introduced, is also used now widely as an initial therapy. However, no large-scale interventional trial has been conducted to show which of these three initial medication can give the greatest benefit in terms of reduced cardiovascular disease risk in the Japanese hypertensive patients.
ISSN:1064-1963
1525-6006
DOI:10.1081/CEH-120019146